Form 4: United Therapeutics CEO Exercises Options, Sells Shares

United Therapeutics CEO Martine Rothblatt exercised stock options and sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), engaged in transactions involving the company's common stock.
• On September 12, 2025, Rothblatt exercised 4,000 stock options at an exercise price of $120.26 per share.
• Concurrently on September 12, 2025, Rothblatt sold a total of 4,000 shares of common stock at weighted average prices of $402.21, $403.91, and $404.89 per share.
• On September 15, 2025, Rothblatt exercised an additional 4,000 stock options at an exercise price of $120.26 per share.
• Also on September 15, 2025, Rothblatt sold a total of 4,000 shares of common stock at weighted average prices of $397.7086 and $398.1889 per share.
• All reported transactions were executed pursuant to a pre-arranged Rule 10b5-1 trading plan established on May 2, 2025.
• Following these transactions, Rothblatt directly owns 130 shares of common stock.
• Indirect beneficial ownership includes 166 shares by spouse and 644,193 shares held across various family trusts.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive due to the significant profit realized by the insider from exercising options and selling shares. However, as these are routine transactions under a pre-arranged plan, they are largely neutral in terms of new company-specific information for investors.

Positives

• The exercise of stock options at $120.26 and subsequent sale at significantly higher prices (ranging from $397.7086 to $404.89) indicates substantial profitability for the reporting person from their equity compensation.
• The transactions were conducted under a pre-arranged 10b5-1 trading plan, demonstrating a structured and compliant approach to insider stock sales.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors, although these are routine transactions for executive compensation.

Future Outlook

The pre-arranged 10b5-1 trading plan, under which these transactions occurred, is set to continue until the earlier of the exhaustion of a tranche of 294,000 stock options that expire on March 15, 2026, or December 31, 2025.

Management Comments

• The exercise and sale of stock options were pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025.
• The reporting person undertakes to provide full information regarding the number of shares and prices at which transactions were effected upon request to the SEC staff, the issuer, or a security holder.

Industry Context

This Form 4 filing details routine insider transactions under a pre-arranged plan, which is a common practice for executives to manage their equity compensation and personal finances. It does not provide broader industry insights or reflect specific industry trends.

Related Party Transactions

• Shares are held indirectly by the reporting person's spouse and various family trusts, where the reporting person and/or immediate family members are beneficiaries or have shared investment power.

Stakeholder Impact

• Shareholders: The transactions are routine insider sales under a pre-arranged plan and are unlikely to have a significant direct impact on the company's operational performance or strategic direction. They represent an executive monetizing vested equity compensation.
• Management: The transactions reflect the Chairperson & CEO's management of personal equity holdings and compensation.

Next Steps

• The 10b5-1 trading plan will continue until the earlier of the exhaustion of a tranche of 294,000 stock options (expiring March 15, 2026) or December 31, 2025.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions (exercise of options and sale of shares) executed under a pre-arranged 10b5-1 trading plan. Such transactions are generally expected and do not typically signal new fundamental information about the company's performance or future prospects. While the insider realized a significant profit, this is a personal financial event rather than a corporate one. Therefore, based solely on this filing, there is no new information to warrant a change in investment thesis, leading to a 'hold' recommendation.

Keywords

UTHR, United Therapeutics, Martine Rothblatt, Form 4, Insider Trading, Stock Options, Share Sale, 10b5-1 Plan, Beneficial Ownership